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INTRODUCTION
Rheumatoid arthritis (RA) is an autoimmune inflammatory
disease mainly affected the peripheral joints, but extra-artic-
ular systems are often affected. Anemia is one of the common
extra-articular manifestations in RA. The prevalence of ane-
mia is 26.9%-77.6% in patients with RA (1). The leading
cause of the anemia in RA is chronic inflammation, with the
pattern of a normochromic and normocytic anemia. It is asso-
ciated with decreased serum iron and total iron-binding capac-
ity (TIBC), but iron store is increased or normal. Iron defici-
ency anemia due to long-term use of non-steroidal anti-in-
flammatory drugs (NSAIDs) and folate deficiency due to me-
thotrexatetherapy also result in the anemia in RA (2). Hemolyt-
ic anemia is a rare cause of anemia in RA. 
There are possible mechanisms in the anemia of chronic
inflammatory diseases in RA. First, inflammatory cytokines,
such as tumor necrosis factor (TNF)-a, interleukin (IL)-1b
and interferon-g, induce inadequate erythropoiesis in bone
marrow, inhibiting erythroid progenitor differentiation and
driving the apoptosis of erythroid progenitors. Second, the
inflammatory cytokines mediate the inhibition of peripher-
al iron utilization. Third, the erythropoietin production in
response to anemia is relatively impaired. Forth, red cell sur-
vival is slightly reduced in RA patients (2, 3). In general, a
degree of anemia correlates with RA disease activity and serum
TNF-a concentration (4). The patients with anemia are like-
ly to have more severe joint diseases than those without ane-
mia in RA. 
Hepcidin, a 25 amino acid peptide hormone, regulates
intestinal iron absorption, recycling, and tissue storage (5).
Beyond the iron regulation, it is closely linked with inflam-
mation and infection (5, 6). The inflammatory signal, chiefly
IL-6, induces hepcidin synthesis, then the upregulated hep-
cidin decreases duodenal iron absorption and increases seques-
tration of iron by macrophage, resulting in hypoferremia (7).
This is another possible mechanism of anemia of chronic in-
flammatory disease such as RA and systemic lupus erythe-
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Serum Pro-hepcidin Could Reflect Disease Activity in Patients with
Rheumatoid Arthritis
The aim of this study was to analyze the relationship between serum pro-hepcidin
concentration and the anemia profiles of rheumatoid arthritis (RA) and to estimate
the pro-hepcidin could reflect the disease activity of RA. RA disease activities were
measured using Disease Activity Score 28 (DAS28), tender/swollen joint counts,
erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP). Anemia profiles
such as hemoglobin, iron, total iron binding capacity (TIBC), ferritin, and transferrin
levels were measured. Serum concentration of pro-hepcidin, the prohormone of hep-
cidin, was measured using enzyme-linked immunosorbent assay (ELISA). Mean
concentration of serum pro-hepcidin was 237.6±67.9 ng/mL in 40 RA patients. The
pro-hepcidin concentration was correlated with rheumatoid factor, CRP, ESR, and
DAS28. There was a significant correlation between pro-hepcidin with tumor necro-
sis factor (TNF)-a, interleukin (IL)-1b, and IL-6. The pro-hepcidin concentration was
significantly higher in the patients with active RA (DAS28>5.1) than those with inac-
tive to moderate RA (DAS28≤5.1). However, the pro-hepcidin concentration did not
correlate with the anemia profiles except hemoglobin level. There was no difference
of pro-hepcidin concentration between the patients with anemia of chronic disease
and those without. In conclusion, serum concentration of pro-hepcidin reflects the
disease activity, regardless of the anemia states in RA patients, thus it may be anoth-
er potential marker for disease activity of RA.
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matosus (SLE). This is supported by following two evidences.
First, hepcidin mRNA level in adipose tissue correlates with
IL-6 and C-reactive protein (CRP) (8). Second, when IL-6 is
infused to healthy individuals, the hepcidin level increases,
and serum iron and transferrin saturation decrease (7). 
The aim of this study is to analyze the relationship between
serum pro-hepcidin, a prohormone of hepcidin, concentra-
tion and the anemia profiles of RA and to determine whether
the pro-hepcidin could reflect RA disease activity.
MATERIALS AND METHODS
Patients 
Forty patients with RA were enrolled in this study and the
patients all met the American College of Rheumatology 1987
revised criteria for the classification of RA (9). Informed con-
sents were obtained from the patients before the study, and
this study was approved by the Ethical Committees in Konkuk
Medical Center (KUH1010061). 
Disease activity evaluation in RA patients
When the sera were obtained, clinical assessments, such as
tender joint counts, swollen joint counts, and 100 mm-visu-
al analogue scale (VAS) were performed by one rheumatolo-
gist. Erythrocyte sedimentation rate (ESR), CRP, the titer of
IgM rheumatoid factors (RF) and the titer of antibodies to
cyclic citrullinated peptide (anti-CCP Ab) were measured.
From these clinical and laboratory data, Disease Activity Score
28 (DAS28) was calculated. 
Laboratory study for anemia
Laboratory analysis for anemia, such as complete blood count
(CBC), hemoglobin (Hb), hematocrit, serum iron, TIBC, fer-
ritin, and transferrin levels, are measured using standard lab-
oratory methods. Anemia was defined as Hb <13 g/dL in
male and <12 g/dL in female. Anemia of chronic disease was
defined as normo- to microcytic anemia with decreased serum
iron concentrations, normal to decreased transferrin levels
and normal or increased serum ferritin levels (10). Patients
whose anemia did not result from anemia of chronic disease
were excluded in this study.
Serum concentration of pro-hepcidin and proinflammato-
ry cytokines (TNF-a, IL-1b, and IL-6)
Serum pro-hepcidin concentration was measured using the
DRG
� Hepcidin Prohormone Enzyme Immunoassay Kit
(DRG Instruments, Marburg, Germany), according to the
manufacturer’s instructions. Pro-hepcidin is the 84 amino
acid precursor of the active hepcidin peptide. 
TNF-a, IL-6, and IL-1b in serum were measured by sand-
wich enzyme-linked immunosorbent assay (ELISA), as pre-
viously described (11). Briefly, 4 mg/mL of monoclonal anti-
bodies to human TNF-a, IL-6, and IL-1b (R&D Systems,
Minneapolis, MN, USA) was added to a 96-well plate (Nunc,
Denmark) and incubated overnight at 4℃. After incubating
the plate with a blocking solution consisting of phosphate
buffered saline (PBS) containing 1% bovine serum albumin
and 0.05% Tween 20 for 2 hr at room temperature, test sam-
ples and the standard recombinant cytokines (R&D Systems)
were added to the 96-well plate and the plate incubated at
room temperature for 2 hr. After washing four times with
PBS containing Tween 20, 200 ng/mL of biotinylated mon-
oclonal antibodies to human cytokines (R&D Systems) were
added and the reaction was allowed to proceed for 2 hr at room
temperature. After washing, 2000-fold diluted streptavidin-
alkaline-phosphatase (Sigma Bioscience, St. Louis, MO, USA)
was added, and the reaction was allowed to proceed for a fur-
ther 2 hr. After the plates were washed four times, 1 mg/mL
of p-nitrophenylphosphate (Sigma) dissolved in diethanola-
mine (Sigma) was added to induce the color reaction, which
was stopped by adding 1N NaOH. An automated microplate
reader (Vmax, Molecular Devices, Palo Alto, CA, USA) set at
405 nm was used to measure the optical density. The sensitiv-
ity limit was 15.6 pg/mL for TNF-a, IL-6, and IL-1b. Recom-
binant human cytokines diluted in culture medium over a
concentration range of 10-2,000 pg/mL were used as cali-
bration standards. A standard curve was drawn by plotting
optical density versus the log of the concentration of recom-
binant cytokines.
Statistical analysis
Data are expressed as the mean±standard deviation (SD).
Statistical analysis was performed using Student’s t test for
independent samples. Correlation coefficients were deter-
mined by Pearson’s correlation test. P values less than 0.05
were considered significant. 
RESULTS
The clinical characteristics of the 40 RA patients were as
follows: age 57.6±13.3 yr, disease duration 52.6±79.6
months, duration of morning stiffness 45.4±66.5 min, and
DAS28 4.64±18.4. RF was positive (>18 IU/mL) in 67.5%
of the patients. 75% of the patients had positive anti-CCP
Ab (>20 Unit/mL). Table 1 shows the additional clinical data
of the RA patients included in the study. 
The laboratory profiles relative to anemia were as follows;
Hb 11.9±1.5 g/dL, serum iron 63.9±35.9 mg/dL, TIBC
291.6±43.9 mg/dL, ferritin 116.4±168.6 ng/mL, and trans-
ferrin 235.3±37.9 ng/mL. When the patients were divided
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mia of chronic disease had lower serum iron (78.9±39.9 vs.
47.4±20.7 mg/dL, P<0.001), higher ESR (32.2±23.9 vs.
44.8±24.3 mm/hr, P=0.02), and higher CRP (1.3±1.8 vs.
3.4±5.3 mg/dL, P=0.03), than the patients without ane-
mia. Other clinical and laboratory parameters (disease dura-
tion, morning stiffness, 100 mm VAS, DAS28, tender/swollen
joint counts), RF and anti-CCP Ab titers were not different
between anemic and non-anemic groups. 
In 40 RA patients, the mean concentration of serum pro-
hepcidin was 237.6±67.9 ng/mL. Serum pro-hepcidin con-
centration negatively correlated with serum iron (r=-0.23,
P=0.04), but it did not correlate with TIBC, ferritin and trans-
ferrin. There was no difference of pro-hepcidin concentration
between the patients with anemic and non-anemic groups.
Next, we determined the relationship between serum pro-
hepcidin concentration and RA disease activity parameters.
The pro-hepcidin concentration correlated with DAS28 (r=0.4,
P<0.001), tender joint count (r=0.3, P=0.003), RF titer (r=
0.51, P<0.001), ESR (r=0.53, P<0.001), and CRP (r=0.22,
P=0.05). When the patients were divided into two groups
using DAS28 score: patients with active RA (DAS28 >5.1,
n=14) and those with inactive to moderate RA (DAS28 ≤5.1,
n=26), the serum pro-hepcidin concentration was higher in
patients with active disease than in those inactive to moderate
disease (271.7±95.7 ng/mL vs. 219.3±37.6 ng/mL; P=0.01,
Table 2). There is no difference of pro-hepcidin concentration
in the groups with inactive and moderate diseases. However,
the pro-hepcidin concentration was not dependent of current
medication including steroid, disease modifying anti-rheu-
matic drugs (DMARDs), and biologics. 
Finally, we analyzed the relationship between pro-hepcidin
with proinflammatory cytokines such as TNF-a, IL-1b, and
IL-6. Mean concentrations of serum TNF-a, IL-1b, and IL-6
were 197.8±22.6 pg/mL, 252.5±5.8 pg/mL, and 262.3
±17.3 pg/mL, respectively. There was significant correla-
tion between the serum concentration of pro-hepcidin with
the serum concentrations of TNF-a (r=0.58, P<0.001), IL-
1b (r=0.59, P<0.001), and IL-6 (r=0.4, P=0.01). 
DISCUSSION 
Hepcidin synthesis is regulated by extrinsic or intrinsic
iron loading, anemia, and hypoxemia. Moreover, the hepcidin
production is induced by a particular cytokine, IL-6, during
inflammation (7). In a previous study, IL-6 is induced with-
in 3 hr after injection of lipopolysaccharide (LPS) and urinary
hepcidin peaks within 6 hr, followed by decrease in serum
iron (12). IL-6 is one of the proinflammatory cytokines, which
has central role in the pathogenesis of RA, a representative
inflammatory disease. IL-6 induces acute phase response, and
differentiates B and T cells, and promotes joint destruction
in RA (13-15). Serum levels of IL-6 are correlated with RA
disease activity and clinical symptoms. Because anemia is a
common extra-articular manifestation of RA, we hypothe-
sized IL-6-hepcidin could be the possible link in RA to the
anemia. 
A recent study showed that RA patients have higher serum
concentration of pro-hepcidin than patients with SLE and
healthy volunteers, but the pro-hepcidin concentration doesn’t
correlate with RA disease activity scores, TNF-a, or IL-6 (14).
However, in our study, serum pro-hepcidin concentration cor-
related with RA disease activity parameters such as DAS28,
tender joint count, ESR and CRP. The serum concentration
of pro-hepcidin also correlated with proinflammatory cyto-
kines, such as TNF-a, IL-1b, and IL-6. In the previous study,
serum concentrations of TNF-a, IL-1b, and IL-6 are correlat-
ed with RA disease activity indexes, such as DAS28, ESR,
and CRP (16-18). The roles of these proinflammatory cyto-
kines in the RA pathogenesis are well known and the inhi-
bitors of each cytokines are used universally as the therapy
for active RA. Correlation of pro-hepcidin with proinflam-
matory cytokines suggests that pro-hepcidin was induced by
the proinflammatory cytokines, especially IL-6. Moreover,
Data were expressed by mean±SD. 
DAS28, Disease Activity Score 28; Anti-CCP antibody, anti-cyclic citrul-
linated peptide antibody.
Parameters Findings
Age (yr) 57.6±13.3
Sex (male:female) 4:36
Disease duration (months) 52.6±79.6
Morning stiffness (min) 45.4±66.5
DAS28 4.64±1.84
Visual analogue scale (mm) 34.5±1.2
Tender joint counts  7.9±6.6
Swollen joint counts  4.6±6.3
Erythrocyte sedimentation rate (mm/hr) 38.2±24.9
C-reactive protein (mg/dL) 2.3±4.0
Rheumatoid factor (IU/mL) 90.1±157.4
Anti-CCP antibody (unit/mL) 73.6±91.9
Table 1. Clinical characteristics of the 40 patients with rheuma-
toid arthritis
Data were expressed by mean±SD. 
TIBC, total iron binding capacity; DAS, Disease Activity Score.
Parameters  DAS>5.1
(n=14)
DAS≤5.1
(n=26)
P
value
Hemoglobin (g/dL) 11.5±1.7 12.1±1.3 0.06
Iron (mg/dL) 57.5±26.0 67.4±40.4 0.18
TIBC (mg/dL) 269.6±43.4 303.5±40.1 0.001
Ferritin (ng/mL) 197.8±247.5 73±82.5 0.01
Transferrin (ng/mL) 219.8±45.3 250.8±23.1 0.04
Pro-hepcidin (ng/mL) 271.7±96.9 219.3±36.4 0.009
Table 2. Laboratory parameters relative to anemia and the serum
concentrations of pro-hepcidin in the 14 patients with active RA
(DAS>5.1) and the 26 patients with inactive to moderate RA (DAS
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when the patients were divided two groups by disease activ-
ities, the RA patients with active disease had higher concen-
tration of serum pro-hepcidin than those with inactive to mod-
erate disease. This result suggested that serum pro-hepcidin
concentration could be another useful marker for RA disease
activity as acute phase reactants, active joint counts or proin-
flammatory cytokines. Our results showed different results
from the previous study in RA (14), it is plausible that the
patients in our study were older Asian with more active RA
than the patients who were enrolled in the previous study
(mean age: 57.6 vs. 46.4 yr, and mean DAS28: 4.64 vs. 3.59).
These differences of characteristics of patients could be the
cause of different results. Further study should be warranted
to elucidate this contradictory result.
On the other hand, pro-hepcidin did not correlate anemia
profiles, except for negative correlation with serum iron con-
centration. It was postulated that serum pro-hepcidin could
not represent the bioactive hepcidin (12), thus serum pro-hep-
cidin concentration did not reflect actual anemic parameters,
as supported by a previous studies (19, 20). After injection
of LPS, serum pro-hepcidin levels don’t change significantly,
although pro-inflammatory cytokine induction, urinary hep-
cidin excretion, and serum iron are decreased (12). No differ-
ence of serum pro-hepcidin between the RA patients with or
without anemia may be explained that serum pro-hepcidin
could not reflect the iron state exactly in human disease set-
ting. Another explanation is that hepcidin is overproduced
by the inflammatory response in RA, and the over-expressed
hepcidin might disturb the normal physiologic response in
the iron metabolism. Many arguments on the correlation bet-
ween pro-hepidin and anemia indicate that measurement of
serum pro-hepcidin could not substitute bioactive hepcidin.
Therefore, available method for measurement of hepdicin is
needed to reveal accurate relationship of inflammatory diseases
and anemia. We postulate that there is different clinical signifi-
cance between hepcidin and pro-hepcidin, the former might
regulate iron metabolism and the latter might regulate inflam-
matory process. More research is needed to serial measure-
ment of serum pro-hepcidin in same patients as the disease
activity changes. 
In conclusion, proinflammatory cytokines play a major role
in the development of anemia of RA, as they inhibit erythro-
poiesis, and hepcidin might involve in minor mechanism of
anemia in the inflammatory disease, as it regulates iron meta-
bolism inappropriately. Hepcidin or pro-hepcidin might play
an important role in RA, as the mediator linking anemia and
the inflammatory cytokines. Pro-hepcidin could be another
useful marker for RA disease activity.
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